▶ AMYLIN RECEPTOR AGONIST · SUBTOPIC · MECHANISM
AMYLIN RECEPTOR AGONIST Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Long-acting amylin analog. Activates amylin and calcitonin receptors to slow gastric emptying and modulate satiety signaling. Forms the the amylin receptor agonist-half of the CagriSema combination program with the long-acting GLP-1 agonist.
PHARMACOKINETIC HALF-LIFE
Reported half-life for AMYLIN RECEPTOR AGONIST: ~7 days (once-weekly dosing). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
AMYLIN RECEPTOR AGONIST is a defined sequence: 37-residue amylin analog with C20-fatty-acid albumin tether. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Lau 2021 Lancet · dose-dependent placebo-subtracted weight loss to ~10.8% at 26 weeks.
Frias 2023 Lancet · combination outperforms monotherapy components in T2D + obesity Phase 2; Phase 3 REDEFINE program ongoing.
MECHANISM Q+A
▶ What is the amylin receptor agonist?
the amylin receptor agonist is a synthetic long-acting amylin analog developed by the originator pharma sponsor for once-weekly subcutaneous administration. Native amylin is co-secreted with insulin by pancreatic beta cells and promotes satiety, slowed gastric emptying, and reduced postprandial glucagon.
▶ How is the amylin receptor agonist different from pramlintide?
Pramlintide (Symlin) is the short-acting amylin analog FDA-approved 2005 for adjunctive use with insulin in type 1 and insulin-treated type 2 diabetes. the amylin receptor agonist is the long-acting analog with C20 fatty-acid albumin tether enabling once-weekly dosing for weight management.
▶ What is CagriSema?
CagriSema is the fixed-ratio combination of the amylin receptor agonist + the long-acting GLP-1 agonist developed by the originator pharma sponsor as a single weekly injection for obesity. Phase 2 trials reported greater weight loss than either monotherapy.
▶ Is the amylin receptor agonist FDA-approved?
Not yet as of 2026-05. The Phase 3 REDEFINE program for CagriSema in obesity is ongoing.
▶ How does the amylin receptor agonist work?
Dual agonism at the amylin receptor (a heterodimer of calcitonin receptor + RAMP1/2/3) and the calcitonin receptor in area postrema and arcuate nucleus, reducing food intake and promoting satiety. Mechanism complements GLP-1 receptor signaling.
CITED LITERATURE
- Lau DCW, et al.. Once-weekly the amylin receptor agonist for weight management in people with overweight and obesity. Lancet 2021. PMID 34247670. link
- Frias JP, et al.. Efficacy and safety of co-administered once-weekly the amylin receptor agonist 2·4 mg with once-weekly the long-acting GLP-1 agonist 2·4 mg in type 2 diabetes. Lancet 2023. PMID 37364590. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19